Dosage Calculator
Determine the appropriate
dosage for your patient
Look over the patient treatment profile and administration features of RAVICTI
For patients with urea cycle disorders (UCDs), controlling ammonia is a process that typically includes dietary modifications, supplements, and sometimes nitrogen scavenger therapies. As the only oral liquid treatment for patients with UCDs with no pills or powders to prepare, RAVICTI is made to fit today’s busy lives.1,2
Remove the childproof cap on the RAVICTI bottle by pushing down on the cap while twisting it to the left. Then, attach the reclosable bottle cap adapter onto the bottle by twisting right.
Once the oral syringe is ready, place it into the mouth. Push the plunger to squirt all of the medicine directly into the mouth.
Ensure the full dose of RAVICTI is swallowed completely by drinking liquid or eating some food. Breakfast, lunch, or dinner, RAVICTI can work with the timing of your patients’ meals.1
Determine the appropriate
dosage for your patient
Determine your patient’s plasma
PAGN ratio and urinary PAGN level
References: 1. RAVICTI (glycerol phenylbutyrate) Oral Liquid [prescribing information] Horizon. 2. Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32. doi:10.1186/1750-1172-7-32.
RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).
The most common adverse reactions reported in clinical trials (at least 10% of patients) were:
Please see Full Prescribing Information.
RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).
The most common adverse reactions reported in clinical trials (at least 10% of patients) were:
Please see Full Prescribing Information.